Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

Novimmune S.A.. (9/10/14). "Press Release: Novimmune Appoints Adrian Mills as Chief Business Officer and Member of the Executive Committee". Geneva.

Organisations Organisation Novimmune S.A.
  Organisation 2 GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Group GlaxoSmithKline (GSK) (Group)
Products Product NI-0101 (Novimmune)
  Product 2 emapalumab (NI-0501)
Persons Person Mills, Adrian (Novimmune 201409– CBO before GSK since 2000)
  Person 2 Barbut, Jack (Novimmune 201012–201512 CEO until 12/15)

Novimmune announced today that it has appointed Adrian Mills as the company's Chief Business Officer and member of the Executive Committee, with immediate effect. Adrian will be leading Novimmune's commercial development activities as well as business development. David Slack, Head of Corporate and Business Development, is leaving Novimmune to focus on opportunities outside the Company.

Jack Barbut, Chief Executive Officer of Novimmune, commented: "I am pleased to welcome Adrian as Chief Business Officer. He brings over 20 years of experience as a pharma-ceutical executive with a particular focus on the commercialization of orphan drugs."

Adrian Mills is a British citizen joining Novimmune from GlaxoSmithKline plc (GSK), where he held various strategic and operational positions from 2000 until 2013 in Europe and SE Asia. Most recently Adrian was European Commercial Director for Rare and Critical Diseases. Prior to GSK, Adrian worked in management consulting and investment banking in the life sciences sector. He holds an MBA from the London Business School and an MA (Hons) Engineering from Queens' College, Cambridge.

Thanking David Slack for his contribution, Jack Barbut said: "David has made a valuable contribution to our business development efforts and in general at the Executive Team level. We wish him every success for his future."

About Novimmune

Novimmune SA is a leading drug discovery and development company focused on the creation of antibody-based drugs to benefit patients with inflammatory, auto-immune and other disorders. To date, Novimmune has advanced seven drug candidates to treat a range of conditions. The company has a diverse clinical pipeline that includes NI-0501, NI-0101 and NI-1401.

NI-0501 is an anti-interferon gamma monoclonal antibody that is currently in a Phase II study as a treatment for the orphan disease Hemophagocytic Lymphohistiocytosis, a potentially lethal inflammatory syndrome.

NI-0101 is a first-in-class anti-TLR4 monoclonal antibody. TLR4 is an important receptor on the pathway leading to the activation of the innate immune system. As such, it has been implicated as a target in drug discovery for a range of conditions including rheumatoid arthritis, lung disease, diabetes, and kidney disease. NI-0101 has recently successfully completed a Phase I clinical program and Novimmune intends to initially progress it as potentially the first personalized medicine for rheumatoid arthritis.

NI-1401 is a differentiated anti IL-17 monoclonal antibody that binds the 3 forms of IL-17 A and F. It was licensed to Genentech, prior to Phase I initiation, in 2010. Genentech has assumed all responsibility and costs for development and is expected to announce initiation of a Phase II clinical program in early 2015.

Novimmune has also developed a proprietary bi-specific antibody platform to help further expand its pipeline.

In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for orphan drug applications.

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Novimmune S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top